AsherBio

Seismic Therapeutic Selected for BioSpace’s NextGen Class of 2023

Cambridge, Mass., January 4, 2023 – Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, announced today it has been selected for BioSpace’s NextGen “Class of 2023” featuring the 25 most promising new life sciences companies in North America that launched between September 2021 and September 2022 with a Series A funding.

“At a time when there is so much exciting scientific innovation in the biopharma industry, we are honored to be recognized as one of the most promising New Life Science Companies on the BioSpace NextGen Class of 2023 List,” said Jo Viney, PhD, CEO of Seismic Therapeutic. As we start the new year, I and our growing, dedicated team of Seismonauts are energized to continue to rapidly advance our pipeline of innovative immunology therapies derived from our IMPACT platform.”

BioSpace has been recognizing the most exciting startups in biotech and pharma for the past nine years in its NextGen list. Organizations across all therapeutic areas are considered, and 25 companies were selected this year. BioSpace’s editorial team analyzed multiple components as determining factors: finance, collaborations, pipeline, growth potential and innovation.

The complete NextGen “Class of 2023” list can be viewed on BioSpace.

About BioSpace

BioSpace is the digital hub for life science news and jobs. We provide essential insights, opportunities and tools to connect innovative organizations and talented professionals who advance health and quality of life across the globe. Learn more and subscribe at www.biospace.com

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

AsherBio

Seismic Therapeutic Named Emerging Company of the Year in Life Sciences at 2022 NEVY Awards

Cambridge, Mass., December 9, 2022 – Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, announced today the company was selected as the Emerging Company of the Year in Life Sciences by the New England Venture Capital Association (NEVCA) in its 10th annual NEVY Awards, which recognizes and celebrates the top innovators, investors and companies in the region.

“We are thrilled to be named Emerging Company of the Year in Life Sciences and thank the New England Venture Capital Association for recognizing our vision and momentum,” said Jo Viney, PhD, CEO of Seismic Therapeutic. “We look ahead with excitement as our dynamic team works to advance our IMPACT platform to develop innovative immunology therapies that make a difference for patients.”

Seismic Therapeutic representatives received the award on December 8th at the annual celebratory event at the House of Blues in Boston. The NEVYs honor both early- and late-stage companies, as well as the venture capitalists who support them, and cover a broad spectrum of the region’s thriving industry clusters, including technology, life sciences, healthcare and medtech.

About the New England Venture Capital Association
The New England Venture Capital Association (NEVCA) works toward a collaborative, inclusive, and prosperous innovation ecosystem. Through unique programs, critical policy work, and dynamic local events and regional marketing, the NEVCA invests in the entrepreneurial ecosystem on behalf of the VC community. VCs are only as successful as the entrepreneurs in whom they invest and the environments in which those investments grow. We don’t just host events: we act as a network, catalyst, and resource for the innovation economy, from celebrations to education; legislative advocacy to workforce development. Follow @NewEnglandVC on Twitter, or check out www.newenglandvc.org.

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

AsherBio

Founder Q&A with Tim Springer, PhD

A catalyst for biotech innovation and recent Lasker Award honoree

Timothy A. Springer, PhD

Latham Family Professor
Professor of Biological Chemistry and Molecular Pharmacology, Professor of Medicine, Harvard Medical School
Principal Investigator, Program in Cellular and Molecular Medicine, Division of Hematology/Oncology, Department of Medicine, Boston Children’s Hospital

 


Seismic Founder Tim Springer, PhD, is a world leader in structural biology and immunology. He was recently honored as a co-recipient of the 2022 Albert Lasker Basic Medical Research Award for discoveries concerning integrins, key mediators of cell-matrix and cell-cell adhesion in physiology and disease. He is a founder and private investor in numerous biopharmaceutical companies, including Moderna, Tectonic, Scholar Rock and Morphic Therapeutic, and his research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and autoimmune diseases. We’re proud that Dr. Springer is also a founding investor and scientific founder of Seismic Therapeutic.

To launch our Founders Q&A Series, Seismic Chief Business Officer Maude Tessier had a wide-ranging discussion with Dr. Springer about his work, his recent Lasker Award and how his research led to Seismic. 

Maude Tessier:

You were recently honored with the prestigious Lasker Award, for your discovery of a family of proteins – integrins – and their essential role in cell trafficking in health and disease. Can you offer your perspective on what it feels like to have this work recognized and its potential impact?

Tim Springer:

It’s a real honor for me to be recognized by my scientific peers and superiors, because many of the people on that committee are Nobel Prize laureates and they have a very good taste in science.

We are just now being recognized for discoveries that Erkki Ruoslahti and Richard Hynes and I made about 40 years ago. My discoveries date from 1979 when I identified the first molecule that became an integrin, up to 1985 when we published amino acid sequences, and then in 1986 when others recognized that the sequences they had determined for extracellular matrix receptors were homologous to the sequences we published, and the integrin family was recognized as being quite broad in scope. I think that one reason this recognition took so long was that integrins are interdisciplinary and important players in many, many fields of science, but they don’t dominate a single field uniquely like some of the other scientific contributions that have been recognized by the Lasker award.

Can you further elaborate on how your work recognized by the Lasker Award opened up new therapeutic strategies that are being used in the clinic today – especially for the challenging area of autoimmune diseases?

I think what really became important over the many years was the therapeutics that were discovered to target integrins – two came directly from my research. I first reported on LFA-1 in 1981, and now there is a small molecule that is directed to LFA-1. This molecule was approved for dry eye, and it’s estimated that it treats over a 100,00 patients a year who have this autoimmune disease.

The second big success is Entyvio or vedolizumab, an antibody that is directed to the integrin alpha4/beta7 that is responsible trafficking of cells to the intestine. I founded a company based on this work, called LeukoSite. LeukoSite was acquired by Millennium Pharmaceuticals, who then in turn was acquired by Takeda. Entyvio prevents trafficking of lymphocytes from the bloodstream into mucosal tissues, and reduces the inflammation that causes ulcerative colitis and Crohn’s disease. These are both very successful therapeutics.

With the Lasker Award coming 40 years after your first discovery of integrins, you’ve been able to see this discovery translated into approved drugs. Did you somehow know that you had made a meaningful discovery, and how does it feel to now see drugs on the market that are derived from your work?

I thought alpha4/beta7 – which ultimately became the target for the drug Entyvio – could be very important because normal anti-inflammatories at the time were just broadly active on many kinds of cells. I thought that  targeting integrins would be much more selective, because it could achieve specificity for certain subtypes of leukocytes that were going to be trafficking to the gut and that it could reduce the potential risk of side effects that can occur if you block the whole immune response.

What I didn’t fully appreciate at the time – because I’m a PhD and I’d never treated patients – is how impactful  a drug like Entyvio can be to patients with ulcerative colitis or Crohn’s disease, which is pretty remarkable.

Throughout my life, I’ve met many people who’ve benefited from drugs that I had a role in developing, either through basic science discovery or from starting companies. That’s been incredibly gratifying. For example, there’s a person who works for the Lasker Foundation, who shared with me that Entyvio had made a huge difference. He’s had ulcerative colitis all of his life, and he divides his life into pre-Entyvio and after Entyvio – it’s that big of a change in the quality of his life.

You have accomplished so much, from your illustrious academic career and biotech startups to drugs in the clinic and approved. What continues to drive you? What keeps you engaged and motivated?

There are so many new technologies now, and so much more to come – it’s very exciting. When I started out in my career in 1971, I there was no biotech industry. Genentech, Biogen, and Genetics Institute were all founded between 1976 and 1980. Those companies were working on recombinant proteins that could replace natural proteins, like erythropoietin and human growth hormone. No one then was thinking about synthetic proteins.

Monoclonal antibodies hadn’t been invented when I started my PhD. I was fortunate to do a postdoc with César Milstein, who had just discovered monoclonal antibodies. And now monoclonal antibodies are a mainstay of currently approved therapeutics. Then biotech evolved further and now we have new modalities, like messenger RNA. Who would’ve thought that messenger RNA could become an important drug product – so that, like millions of people, I just got my latest COVID booster. Also, there’s cell therapy, gene therapy, virally vectored vaccines, and genetic CRISPR. And there’s just more and more on the horizon.

What perspective or advice can you offer others – in academia or industry – who are working on novel areas of discovery, looking back on lessons learned in your career?

Do something that is just very new biology, but so important and so unknown that many new receptor ligand interactions or other new conceptual advances are likely to come from it. Understand the scientific basis for everything you’re doing, and don’t be a specialist. If you’re working on other tools or proteins that people have given you, understand how they work so you can put the big picture together. And keep on learning and keep on challenging yourself. And then if that works out, start a company.

This is currently my model for starting companies: do something in your laboratory that has big potential. And then if you think it is much more than you can do in your laboratory to translate the science into products, start a company.

For example, along with Eugene Butcher’s laboratory and Uli von Andrian, Mike Lawrence and I discovered  the three-step model of how leukocytes leave the circulation to accumulate in tissues because they perceive a signal that something is awry. After we published it in 1991, I said, “Well, this is an area that is way bigger than something I can really address in my laboratory, and so we need to start a company to truly address this.” And the company LeukoSite was born.

This process is also how Seismic Therapeutic came about.

Immunology and autoimmune diseases have been a challenging area for drug development. What makes you most excited about Seismic?

At Seismic, we have new vistas on biologics. We are using machine learning to improve the biologics discovery process and have a virtual cycle between structural biology, protein engineering, translational immunology and then machine learning to evolve better and better proteins. The tools that are available now are just so powerful and it continues to evolve.

And it’s really wonderful to collaborate with people who are on the same track with you at a peer level. Often in academics, people find themselves in silos, working in their own area. It’s so nice to have a close collaboration with a company and be all on the same team.

You were the driving force in getting Seismic started. How did the concept of the company come to be? How did these foundational ideas emerge?

Well, we had come across new types of molecules to modify proteins including antibodies, and these modifications could change their properties very dramatically – but would require a lot of optimization, that could be enabled by machine learning, to create medicines. And I thought that would have huge therapeutic implications and in many different kinds of diseases including autoimmunity. I did a lot of research on it and discovered the breadth of what was known, which was staggering, and what the range of diseases was that could be affected, which was also quite wide.

So I put together a set of slides and I presented it to Polaris. And I particularly wanted to attract Alan Crane because he’s such a wonderful person to work with. We started to put together the company, bringing together some scientific leaders and others that I had worked with in the past. And then Jo Viney had some other ideas that she’d been incubating. So she became a co-founder. Jo’s perspectives broadened our platforms, and I’m excited about the drug discovery engine and the very talented team.

At Seismic, we’re integrating machine learning with structural biology and translational immunology to create novel biologics that we hope will transform how autoimmune disease patients are being treated and their quality of life. How do you see the integration of all these different disciplines making an impact in the field? And why did you think this was the right time to start Seismic?

It feels like the field of applying AI to biologics for drug development is just starting. And I think Seismic is really at the forefront of this new area by applying machine learning to biologics drug discovery in several key ways.

First, the new ways we’ve found to optimize protein therapeutics have gained lots of traction. And, with a lot of genome sequences out there, we can explore a lot of sequences through bioinformatics, and then we’ve used machine learning to improve those sequences guided by structural biology. The goal is to use machine learning to get to what we hope is an optimum protein sequence, more quickly.

Second, structure prediction can be done more broadly and easily with machine learning because it enables the ability to make many iterations for new protein modifications simultaneously to change effector functions and yet maintain drug-like properties. And this opens possibilities to make other new kinds of drugs, as well.

Third, the Seismic team is marrying this effort with ‘invisibilization’ where we can design a biologic to avoid immunogenicity, which is a major challenge in the field. So, the idea is to rationally decrease immune responses to any proteins that we would give to patients. I think this is just becoming a reality at this moment. And I think it can have an enormous benefit in a large percentage of patients who receive protein therapies.

You have seen so much happen in the past decade or two in the field of proteins and biologic medicines.  In addition to what we’re doing at Seismic, where do you see the field going in the future?

Well, I think we can engineer protein therapeutics much better than we have in the past. And I think machine learning will contribute a lot to that and allow us to get to the right drug product much more quickly. Machine learning must be done in concert with structural biology and the reality of testing designs both in vitro and in vivo, and we are doing that, and I think that it will have a huge impact. We’re ready for great things at Seismic, with a strong plan and stellar team. I think it’s going to be an outstanding company.

AsherBio

Seismic Therapeutic Congratulates Dr. Timothy A. Springer, Winner of the 2022 Lasker Award

CAMBRIDGE, Mass., September 28, 2022 – Seismic Therapeutic, Inc., today congratulated Timothy A. Springer, PhD, for his selection as a co‑recipient of the 2022 Albert Lasker Basic Medical Research Award, one of the most prestigious awards in medicine. Dr. Springer is a founding investor and academic co-founder of Seismic Therapeutic.

Dr. Springer (Boston Children’s Hospital/Harvard Medical School) is a co-winner of this year’s Lasker Award along with Richard O. Hynes, PhD, (Massachusetts Institute of Technology) and Erkki Ruoslahti, MD, PhD, (Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA) for discoveries in their respective labs concerning a family of transmembrane proteins called integrins. In a statement, the Lasker Foundation cited the work of Drs. Springer, Hynes and Ruoslahti “for discoveries concerning the integrins—key mediators of cell-matrix and cell-cell adhesion in physiology and disease.”

Dr. Springer is the Latham Family Professor and Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, and Principal Investigator and Professor of Medicine, Program in Cellular and Molecular Medicine, Boston Children’s Hospital. His discoveries have led to novel therapeutic strategies to treat a variety of autoimmune disorders, which is the disease area for Seismic’s drug development that integrates machine learning.

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

 

AsherBio

Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

Watertown, Mass., May 3, 2022 – Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier brings over 16 years of company building experience with a multi-disciplinary background in business development, corporate strategy, corporate communications, IP management, and portfolio and program management in public and private biotechnology, pharmaceutical and academic organizations.

“We are very pleased to welcome Maude to the Seismic leadership team. Seismic is in a period of significant growth and Maude will play a vital role in implementing and executing our long-term business, partnering and financing strategy. Her proven track record of cultivating biopharma partnerships and strategic deals to advance new medicines will help drive the tremendous opportunities ahead of us at Seismic,” said Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic. “Maude’s versatile leadership experience across a range of company sizes, deep business acumen and collaborative team spirit are an ideal fit for our team as we chart the course for Seismic as the machine learning immunology company and build a pipeline of novel medicines for autoimmune diseases.”

“I couldn’t be more delighted to join the outstanding team at Seismic at this exciting time when the company is building momentum with its leading-edge platform and promising pipeline candidates,” said Dr. Tessier. “I look forward to working alongside Jo and my Seismic colleagues to drive business strategies and foster opportunities that will enable the company to achieve its goals as an immunology innovator that makes an impact on patients’ lives.”

Dr. Maude Tessier joins Seismic after serving as Chief Business Officer of Ikena Oncology (Nasdaq: IKNA), a clinical-stage biotech company, where she built and managed the business development, legal and corporate strategy functions. At Ikena, she played a multi-faceted role leading key company building initiatives, including the negotiation and execution of a $1B+ strategic partnership with BMS, the strategy and execution of the company rebranding and pipeline expansion into targeted oncology, the acquisition of Amplify Medicines, and as part of the executive team, drove core elements of financing activities resulting in over $260M in private and public capital. Prior to Ikena, she was Executive Director, Business Development and Licensing at Merck & Co, leading oncology partnering in the Boston innovation hub. Dr. Tessier previously served as Assistant Director, Business Development and Strategic Initiatives at Boston Children’s Hospital. She began her career at Xanthus Pharmaceuticals, a venture-backed oncology biotech company in Cambridge, Mass., where she had key roles in business development and program management of a Phase 3 drug candidate leading to its eventual FDA approval. She holds a BSc in Biochemistry from McGill University and a PhD from the Department of Medical Biophysics at the University of Toronto.

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

AsherBio

Seismic Therapeutic Appoints Eric Larson as Senior Vice President of Finance and Heather Vital as Vice President of R&D Strategy

Biotech business leaders bring extensive financial and strategic planning experience across many stages of product development and company growth 

Watertown, Mass., April 13, 2022 – Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Eric Larson as Senior Vice President of Finance and Heather Vital as Vice President of R&D Strategy. These experienced business leaders join Seismic at a pivotal time for the company as it approaches the next stage of growth to build a pipeline of novel biologics to treat autoimmune diseases.

“We are delighted to welcome these two outstanding and accomplished industry leaders to our leadership team, bringing a wealth of expertise in areas of finance and strategic planning to support our future growth,” said Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic. “Eric’s decades of experience in a range of financial leadership roles in the biopharma industry and his proven skills in building operations infrastructure will be invaluable as we evolve Seismic and grow as an immunology platform and pipeline company. Heather’s diverse expertise across R&D strategy and operations, program and alliance management, and commercialization for biopharma companies and her proven skills in developing strategies in new market areas are critical capabilities as Seismic takes on the enormous opportunities ahead of us.”

Eric Larson, Senior Vice President of Finance

“It is exciting to be part of such a talented team at Seismic focused on a new drug development paradigm,” said Mr. Larson. “I look forward to using my experience building and leading finance teams and my operations skills to help a growing organization execute on its strategy, goals and mission to impact the lives of patients.”

Eric Larson brings nearly 30 years of financial leadership experience with private and public companies across multiple industries. His expertise extends across accounting and controls, financial planning, tax and treasury. Prior to joining Seismic, Eric was Vice President of Finance at Pandion Therapeutics where he built the finance and accounting infrastructure in support of its transition to a Nasdaq-listed public company. Previously, he was the Corporate Controller for Proteostasis Therapeutics and the Vice President and Chief Accounting Officer for Northern Power Systems. Earlier in his career, he held financial leadership roles at Biogen Idec, CMGI, Inc., and Ernst & Young.  Eric is a CPA and earned his BA from Grove City College.

Heather Vital, Vice President of R&D Strategy

“This is an invigorating time to join Seismic as the company realizes the potential of integrating machine learning to develop novel treatments for autoimmune diseases,” said Ms. Vital.  “I am eager to leverage my experience to help the company achieve its aspirations as a drug innovator and to create a host of new medicines for patients.”

Heather Vital joins Seismic with more than 15 years of experience across strategic and operational functions, including program and alliance management, portfolio planning and R&D strategy and commercialization. She most recently was Senior Director, Portfolio Strategy and Operations for Relay Therapeutics where she contributed to portfolio strategies for pipeline programs and was responsible for alliance management with a large biopharma partnership and a research collaboration. She served as Senior Director of Program Leadership at Deciphera Pharmaceuticals where she was the program lead for two oncology drug programs including one through product approval. Previously, Heather had a tenure at Biogen, culminating in the role of Director, R&D Strategy and Portfolio Leadership and for several disease areas. Her earlier roles at Biogen included portfolio strategy for spinal muscular atrophy, launching SPINRAZA as part of the global brand team and new product commercialization for the immunology therapeutic area. Heather has a BS from Babson College, MBA from the MIT Sloan School of Management, and a Master of Science (SM) from the Harvard-MIT Health Sciences and Technology Program.

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to treat adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

 

AsherBio

Seismic Therapeutic Launches with $101 Million Series A Financing to Usher in a New Era of Immunology Drug Development Integrating Machine Learning

Company’s IMPACT™ platform accelerates discovery and enables parallel optimization of superior therapeutic and manufacturability properties of novel biologics

Multiple drug programs take a new approach to targeting adaptive immunity to treat autoimmune diseases

Watertown, Mass., February 9, 2022 – Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced its launch and financing of $101 million. The Series A was led by Lightspeed Venture Partners with participation from lead founding investors Timothy A. Springer and Polaris Partners, along with new investors GV, Boxer Capital, Samsara BioCapital, and management and founders. Seismic’s IMPACT™ platform systematically integrates machine learning, structural biology, protein engineering and translational immunology to invent novel biologics and optimize properties with significantly improved efficiency and scale over conventional therapeutics discovery. With this new approach, Seismic Therapeutic is accelerating a pipeline of biologics targeting dysregulated adaptive immunity to treat autoimmune diseases.

“The time is right to move the needle in immunology, as advances in technology now enable us to discover medicines to address complex immune system biology in dramatically improved ways,” said Jo Viney, PhD, Founder, President and CEO of Seismic Therapeutic. “We are leading the next generation of immunology drug development with Seismic’s platform. By integrating machine learning throughout the biologics drug discovery process, we are powered by a systematic and programmable approach to design superior biologics from initial discovery and therapeutic design through to manufacturability.”

The Series A financing will support Seismic Therapeutic’s further advancement toward the clinic of its first two lead drug programs, one targeting Ig (immunoglobulin)-mediated autoimmunity and the other targeting cell-mediated autoimmunity. In addition, the company will continue to build its proprietary IMPACT platform to make further advancements to machine learning technologies applied to immunology therapeutics. 

“This strong financing and syndicate enable Seismic to aggressively advance multiple product candidates to the clinic. Through its leading edge integration of machine learning into drug development, the company is well positioned to be an important innovator in immunology,” said Alan Crane, Founder and Chairman of Seismic Therapeutic and Entrepreneur Partner at Polaris Partners.

IMPACT™ Platform “parallelizes” interdisciplinary components of drug discovery 

The IMPACT platform enables the generation of drug molecules on an unprecedented scale in order to engineer better therapeutic solutions in immunology. The comprehensive integration of machine learning with protein engineering, structural biology and translational immunology enables the accelerated design and analysis of vast numbers of proteins and protein modifications in parallel. This parallelized process enables simultaneous optimization for biologic function and for developability, resulting in the creation of novel biologics with superior properties bypassing the trial and error methods of conventional biologics development with its challenges of balancing multiple factors of efficacy and manufacturability.

“Biologics drug development has undergone extraordinary advances in recent years, and the advent of machine learning working in concert with structural biology and protein engineering offers an entirely new trajectory for creating innovative biologics medicines,” said Timothy Springer, PhD, Founder of Seismic Therapeutic and Professor at Boston Children’s Hospital and Harvard Medical School. “Seismic is taking a major leap forward by fully integrating machine learning throughout the biologics drug development process, whereas earlier efforts to date have generally used machine learning in a much less integrated way.” 

World-class team of drug developers, machine learning innovators, and immunology experts

“The Seismic team has made rapid progress in building a world-class platform for immunology drug innovation, incorporating the power of machine learning and guided by the team’s expert drug hunters, technology integrators and company builders. We look forward to the exciting future for this company and the immunology medicines it will advance for patients,” said Shelley Chu, MD, PhD, Partner, Lightspeed Venture Partners.

The Seismic Therapeutic team brings together experienced biotechnology leaders with decades of industry expertise in company building and drug development. Company leadership includes:

  • Alan Crane, Founder, Chairman
  • Jo Viney, PhD, Founder, President and CEO
  • Nathan Higginson-Scott, PhD, Chief Technology Officer and Senior VP Drug Creation
  • Kevin Otipoby, PhD, Senior VP Immunology
  • Edward Freedman, JD, Chief Financial Officer
  • John Sundy, MD, PhD, Incoming Chief Medical Officer and Head of R&D

Academic Founders of Seismic Therapeutic include world-renowned experts with track records that span decades of pioneering work in immunology mechanisms, structural biology of antibodies and proteins, and machine learning for protein engineering. 

  • Timothy Springer, PhD, Latham Family Professor and Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School; and Principal Investigator and Professor of Medicine, Program in Cellular and Molecular Medicine, Boston Children’s Hospital
  • Debora Marks, MBChB, PhD, Associate Professor of Systems Biology, Harvard Medical School
  • Jeffrey Ravetch, MD, PhD, the Theresa and Eugene M. Lang Professor and head of the Leonard Wagner Laboratory of Molecular Genetics and Immunology at the Rockefeller University
  • Andrew Kruse, PhD, Professor of Biological Chemistry and Molecular Pharmacology, Harvard Medical School
  • Eric Sundberg, PhD, Professor and Chair, Department of Biochemistry, Emory University School of Medicine

About Seismic Therapeutic
Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub. For more information, please visit www.seismictx.com and follow up on Twitter @Seismic_Tx and on LinkedIn.

Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com

 

This links to an external website.

Continue